{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:27:13Z","timestamp":1787135233483,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Novel immunotherapeutic strategies engaging human Natural Killer (huNK) cells have emerged as a promising treatment paradigm; however, their accurate preclinical evaluation requires reliable mouse models capable of supporting functional huNK cell engraftment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We developed and characterized robust\n                      <jats:italic>in vivo<\/jats:italic>\n                      NK-humanized mouse models using immunodeficient human Interleukin-15 (huIL-15) transgenic (Tg) mice.\n                      <jats:italic>In vitro<\/jats:italic>\n                      amplified huNK cells were used as the source of immune cells. Multiple humanized mouse models were evaluated with optimized protocols. Fc\u03b3 receptor knocked-out (Fc\u03b3R-KO) mice were employed to exclusively model antibody-dependent cellular cytotoxicity (ADCC) potential of huNK cells. A resting period prior to adoptive transfer was also introduced and assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our NK-humanized mouse models were developed using in vitro amplified huNK cells, which facilitated the production of large number of viable and functional huNK cells and allowed the engraftment of greater cohort of mice. We identified several key parameters improving the long-term persistence and proliferation of functional huNK cells that maintain important functional cell surface markers. Fc\u03b3R-KO mice exclusively modeled the ADCC potential of huNK cells without the confounding contribution of mouse immune cells. The introduction of a pre-transfer resting period improved tolerability and circumvented potential donor-dependent toxicity issues. Engrafted huNK cells were successfully mobilized in vivo by different NK-based therapeutics, including an engineered IL-2 and an ADCC-enhanced monoclonal antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The NK-humanized huIL-15 Tg mouse models developed here provide a versatile and translationally relevant platform for the evaluation and selection of NK cell-based drug candidates, improving clinical translatability and offering a robust framework for preclinical assessment of novel NK cell immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1887623","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:26:21Z","timestamp":1786944381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of humanized mouse models for the preclinical evaluation of NK cell-based therapies"],"prefix":"10.3389","volume":"17","author":[{"given":"Pauline","family":"Rettman","sequence":"first","affiliation":[{"name":"Sanofi Immuno-Oncology Research","place":["Vitry-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Benhamouche-Trouillet","sequence":"additional","affiliation":[{"name":"Sanofi Immuno-Oncology Research","place":["Vitry-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges A.","family":"Azar","sequence":"additional","affiliation":[{"name":"Sanofi Immuno-Oncology Research","place":["Vitry-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroth\u00e9e","family":"Bourges","sequence":"additional","affiliation":[{"name":"Sanofi Immuno-Oncology Research","place":["Vitry-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Fantin","sequence":"additional","affiliation":[{"name":"Sanofi Immuno-Oncology Research","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhvinder S.","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Sanofi Immuno-Oncology Research","place":["Vitry-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Nicolazzi","sequence":"additional","affiliation":[{"name":"Sanofi Immuno-Oncology Research","place":["Vitry-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01626-2","article-title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123","volume":"41","author":"Gauthier","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095921","article-title":"Human hemato-lymphoid system mice: Current use and future potential for medicine","volume":"31","author":"Rongvaux","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.7.2632.bloodjournal8772632","article-title":"Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells","volume":"87","author":"Mr\u00f3zek","year":"1996","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0293","article-title":"In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells","volume":"100","author":"Cooper","year":"2002","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3392","article-title":"IL-15 is an essential mediator of peripheral NK-cell homeostasis","volume":"101","author":"Ranson","year":"2003","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/jci119258","article-title":"A potential role for interleukin-15 in the regulation of human natural killer cell survival","volume":"99","author":"Carson","year":"1997","journal-title":"J Clin Investig"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.v97.1.14","article-title":"Interleukin 15: Biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912274106","article-title":"Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200045r","article-title":"Enhanced development of functional human NK cells in NOD\u2010scid\u2010IL2rgnull mice expressing human IL15","volume":"36","author":"Aryee","year":"2022","journal-title":"FASEB J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17230","DOI":"10.1038\/s41598-017-17442-7","article-title":"Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse","volume":"7","author":"Katano","year":"2017","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800195","article-title":"Human NK cell development in hIL-7 and hIL-15 knockin NOD\/SCID\/IL2rgKO mice","volume":"2","author":"Matsuda","year":"2019","journal-title":"Life Sci Alliance"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00186","article-title":"Posttransplant hemophagocytic lymphohistiocytosis driven by myeloid cytokines and vicious cycles of T-cell and macrophage activation in humanized mice","volume":"10","author":"Yoshihara","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02082","article-title":"The tumor milieu promotes functional human tumor-resident plasmacytoid dendritic cells in humanized mouse models","volume":"11","author":"Maser","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201546132","article-title":"A novel Flt3\u2010deficient HIS mouse model with selective enhancement of human DC development","volume":"46","author":"Li","year":"2016","journal-title":"Eur J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1038\/s41467-018-07478-2","article-title":"Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses","volume":"9","author":"Douam","year":"2018","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02713-6","article-title":"Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma","volume":"70","author":"Nguyen","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/v15020365","article-title":"Human hematopoietic stem cell engrafted IL-15 transgenic NSG mice support robust NK cell responses and sustained HIV-1 infection","volume":"15","author":"Abeynaike","year":"2023","journal-title":"Viruses"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801137","article-title":"CD137 (4-1BB) engagement fine-tunes synergistic IL-15\u2013 and IL-21\u2013driven NK cell proliferation","volume":"203","author":"Vidard","year":"2019","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200356","article-title":"Crosstalk between human IgG isotypes and murine effector cells","volume":"189","author":"Overdijk","year":"2012","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21087","DOI":"10.1038\/s41598-021-00641-8","article-title":"Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody","volume":"11","author":"Katano","year":"2021","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.532684","article-title":"Improved detection of in vivo human NK cell-mediated antibody-dependent cellular cytotoxicity using a novel NOG-Fc\u03b3R-deficient human IL-15 transgenic mouse","volume":"11","author":"Katano","year":"2020","journal-title":"Front Immunol"},{"key":"B26","article-title":"Visualizing data using t-SNE","volume":"9","author":"Maaten","year":"2008","journal-title":"J Mach Learn Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1158\/1538-7445.am2024-2727","article-title":"Abstract 2727: Pre-clinical development of a novel anti-GPRC5D inducing potent anti-tumor effect through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for multiple myeloma","volume":"84","author":"Bonnevaux","year":"2024","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2017.04.019","article-title":"Reference values for T, B and NK human lymphocyte subpopulations in adults","volume":"12","author":"Apoil","year":"2017","journal-title":"Data Brief"},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050994","article-title":"NKG2D function protects the host from tumor initiation","volume":"202","author":"Smyth","year":"2005","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/35093109","article-title":"Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity","volume":"413","author":"Diefenbach","year":"2001","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030788","article-title":"Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule","volume":"198","author":"Bottino","year":"2003","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3548","article-title":"Analysis of the receptor-ligand interactions in the natural killer\u2013mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the poliovirus receptor (CD155) and Nectin-2 (CD112)","volume":"105","author":"Pende","year":"2005","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ni0508-477","article-title":"Natural killer cell recognition of missing self","volume":"9","author":"K\u00e4rre","year":"2008","journal-title":"Nat Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00251","article-title":"Recognition and regulation of T cells by NK cells","volume":"7","author":"Pallmer","year":"2016","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1158\/1538-7445.am2022-4247","article-title":"Abstract 4247: Development of NK humanized mice models for the in vivo evaluation of NK cell engagers","volume":"82","author":"Rettman","year":"2022","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1158\/1538-7445.am2023-2940","article-title":"Abstract 2940: Use of NK humanized mouse models for the in vivo evaluation of anti-tumor NK-cell therapies","volume":"83","author":"Rettman","year":"2023","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1158\/1538-7445.am2024-5340","article-title":"Abstract 5340: NK-humanized mouse models for the in vivo evaluation of NK cell-based therapies in solid tumors","volume":"84","author":"Rettman","year":"2024","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1158\/1538-7445.am2024-1334","article-title":"Abstract 1334: Evaluation of NK cell combination therapies in mouse models of cancer","volume":"84","author":"Franciszkiewicz","year":"2024","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01880-3","article-title":"A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses","volume":"25","author":"Chupp","year":"2024","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1887623\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:55:59Z","timestamp":1787133359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1887623\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1887623"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1887623","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1887623"}}